Home World News A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated... World News A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 528 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ‘A significant step forwards’ – treating patients with advanced biliary tract... March 30, 2021 Study Updating Meta-analysis Confirms the Deleterious Effect of Systemic Antibiotics on... December 9, 2020 Evaluating Targeted Therapy for People With Advanced Gastric or Gastroesophageal Junction... March 21, 2023 Girls Aloud members to join forces to raise money in Sarah... June 14, 2022 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Ibrutinib ¿Las gammagrafías óseas muestran el cáncer? Innovative cancer spinouts: 3 new projects get green light ¿Los sobrevivientes del cáncer necesitan ser positivos todo el tiempo? Permitirse...
